Article
Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.
International journal of hematology - 1 Feb 2018
Kuwatsuka Yachiyo, Tomizawa Daisuke, Kihara Rika, Nagata Yasunobu, Shiba Norio, Iijima-Yamashita Yuka, Shimada Akira, Deguchi Takao, Miyachi Hayato, Tawa Akio, Taga Takashi, Kinoshita Akitoshi, Nakayama Hideki, Kiyokawa Nobutaka, Saito Akiko Moriya, Koh Katsuyoshi, Goto Hiroaki, Kosaka Yoshiyuki, Asou Norio, Ohtake Shigeki, Miyawaki Shuichi, Miyazaki Yasushi, Sakura Toru, Ozawa Yukiyasu, Usui Noriko, Kanamori Heiwa, Ito Yoshikazu, Imai Kiyotoshi, Suehiro Youko, Kobayashi Shinichi, Kitamura Kunio, Sakaida Emiko, Ogawa Seishi, Naoe Tomoki, Hayashi Yasuhide, Horibe Keizo, Manabe Atsushi, Mizutani Shuki, Adachi Souichi, Kiyoi Hitoshi
Abstract excerpt
Clinical outcomes and the genetic background of acute myeloid leukemia (AML) in adolescent and young adults (AYAs) are known to differ in younger children and older adults. To clarify the impact of genetic mutations on clinical outcomes of AYAs with AML, we analyzed data from the JPLSG AML-05 and JALSG AML201 studies. AYAs aged 15-39 years (n = 103) were included. FLT3-ITD, KIT, CEBPA, NRAS, KRAS, WT1, MLL-PTD,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.